• Users Online: 417
  • Print this page
  • Email this page
Year : 2014  |  Volume : 1  |  Issue : 1  |  Page : 34-55

Ovarian cancer: An ever challenging malady

1 Advanced Centre for Treatment, Research and Education in Cancer(ACTREC), Tata Memorial Centre, Navi Mumbai, India
2 Gynecologic Oncology, Tata Memorial Hospital, Parel, Mumbai, India

Correspondence Address:
Pritha Ray
Assistant Professor and Scientific Officer ‘F’, ACTREC, Kharghar, Navi Mumbai 410210
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2349-3666.240659

Rights and Permissions

Ovarian cancer is the fifth leading cause of cancer related deaths in women with a five year survival rate of only 30–40%. Amongst the three broad subgroups of ovarian cancer, epithelial ovarian cancer is the most common and is divided in mainly five subtypes based histology and clinical behaviour. In patients when the disease is still confined to ovaries, surgery alone is curative for more than 90% patients. Unfortunately, most women are diagnosed with advanced stage disease and recurs in majority despite of debulking surgery and initial response to chemotherapy. Thus ovarian cancer is still a challenge to clinicians which gets more complicated due to asymptomatic nature of the early stage disease and frequent development of resistance to standard therapies. Therefore, researchers worldwide are engaged in identifying markers for early detection of ovarian cancer, investigating molecular mechanisms of chemoresistance, improving detection methods and developing novel therapeutic measures. In this review, we attempt to discuss the contemporary research and challenges associated with epithelial ovarian cancer along with the future improvements in various areas such as early detection of ovarian cancer through Multiplex-Methylation specific PCR (MSP) assay and Serial Analysis of Gene expression (SAGE) assay and identifying new biomarkers, facilitating personalised chemotherapy regime by various chemo-response assays, novel drugs and targeted therapies which will aid in enhancing the overall survival rate in future and overcome this deadly gynaecologic disease.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded284    
    Comments [Add]    
    Cited by others 3    

Recommend this journal